Generated Narrative: PublicationRecord 179628 version: 19; Last updated: 2025-10-13 12:34:35+0000 Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: https://fevir.net/resources/PublicationRecord/179628 identifier: FEvIR Object Identifier/179628, https://pubmed.ncbi.nlm.nih.gov/14706014 title: 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. status: Active author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: Computable Publishing LLC contact: support@computablepublishing.com description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide. UseContexts - Code Value[x] * Citation Classification Type: fevir-platform-use (FEvIR Platform Use) Medline Base copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ approvalDate: 2004-06-15 lastReviewDate: 2019-09-22 classification type: Citation Source classifier: MEDLINE classification type: MEDLINE Citation Owner classifier: National Library of Medicine, Index Section currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish statusDate activity: PubMed Pubstatus of Pubmed period: ?? --> 2004-01-07 05:00:00+0000 statusDate activity: PubMed Pubstatus of Medline period: ?? --> 2004-06-16 05:00:00+0000 statusDate activity: PubMed Pubstatus of Entrez period: ?? --> 2004-01-07 05:00:00+0000 citedArtifact identifier: https://pubmed.ncbi.nlm.nih.gov/14706014, https://doi.org/10.1111/j.1442-2042.2004.t01-1-00748.x, pii/748 Titles - Type Language Text * Primary title English Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Abstracts - Type Text * Primary human use BACKGROUND: The present study was undertaken mainly to investigate whether chemohormonal therapy with estramustine phosphate plus luteinizing hormone-releasing hormone (LHRH) agonist has a more beneficial effect than the hormonal therapy with flutamide plus LHRH agonist for newly diagnosed patients with metastatic prostate cancer. METHODS: A total of 57 patients with metastatic prostate cancer aged 59-80 years (median 74 years) were entered in the study and were randomized to the treatment of estramustine phosphate (560 mg/day) plus LHRH agonist (estramustine group) or flutamide (375 mg/day) plus LHRH agonist (flutamide group) with stratification for the degree of performance status, histological differentiation and bone metastasis. RESULTS: Both of the treatment regimens were well tolerated with similar incidences of adverse drug reactions. The overall response rates (complete response plus partial response) at 12 weeks after treatment in the estramustine and flutamide groups were 76 and 55%, respectively. The median time to objective progression for the estramustine group (25.4 months) was longer than that of the flutamide group (14.6 months). The serum levels of follicle stimulating hormone and testosterone were significantly lower in the estramustine group. CONCLUSIONS: Chemohormonal therapy with estramustine phosphate plus LHRH agonist showed longer clinical progression-free survival than the hormonal therapy with flutamide plus LHRH agonist (P = 0.03), although there was no significant difference in the overall survival. A larger-scaled trial with more statistical power is required to clarify that the former regimen is more beneficial than the latter for newly diagnosed patients with advanced prostate cancer. publicationForm publishedIn type: Periodical identifier: Print ISSN Type/0919-8172, ISOAbbreviation/Int J Urol, ISSN Linking/0919-8172, Medline Title Abbreviation/Int J Urol, NLM Unique ID/9440237 title: International journal of urology : official journal of the Japanese Urological Association publisherLocation: Australia citedMedium: Print volume: 11 issue: 2 articleDate: 2004-02 pageString: 103-9 WebLocations - Classifier Url * Abstract https://pubmed.ncbi.nlm.nih.gov/14706014/ classification type: Publishing Model classifier: Print classification type: Chemical classifier: Androgen Antagonists, Antineoplastic Agents, Hormonal, Gonadotropin-Releasing Hormone, Estramustine, Flutamide classification type: MeSH heading artifactAssessment: ArtifactAssessment: artifact[x] = this resource classification type: Publication type classifier: Clinical Trial, Journal Article, Randomized Controlled Trial classification type: Knowledge Artifact Type classifier: Journal Article artifactAssessment: Classifier added by Computable Publishing LLC classification type: Citation subset classifier: IM contributorship complete: true entry contributor: Noguchi M forenameInitials: M affiliation: Department of Urology, Kurume University School of Medicine, Kurume, Japan. noguchi@med.kurume-u.ac.jp entry contributor: Noda S forenameInitials: S entry contributor: Yoshida M forenameInitials: M entry contributor: Ueda S forenameInitials: S entry contributor: Shiraishi T forenameInitials: T entry contributor: Itoh K forenameInitials: K entry contributor: Kurume-Kumamoto Estracyt Study Group Generated Narrative: Practitioner #contributor0 name: Masanori Noguchi Generated Narrative: Practitioner #contributor1 name: Shinshi Noda Generated Narrative: Practitioner #contributor2 name: Masaki Yoshida Generated Narrative: Practitioner #contributor3 name: Shoichi Ueda Generated Narrative: Practitioner #contributor4 name: Taizo Shiraishi Generated Narrative: Practitioner #contributor5 name: Kyogo Itoh Generated Narrative: Organization #contributor6 name: Kurume-Kumamoto Estracyt Study Group Generated Narrative: ArtifactAssessment #meshHeading0 artifact: PublicationRecord 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. content type: components (if present) include qualifier codings classifier: Aged freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Aged, 80 and over freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Androgen Antagonists freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: administration & dosage Components - Type Classifier * is Major topic Yes content type: components (if present) include qualifier codings classifier: Antineoplastic Agents, Hormonal freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: administration & dosage Components - Type Classifier * is Major topic No content type: components (if present) include qualifier codings classifier: Disease-Free Survival freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Dose-Response Relationship, Drug freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Drug Administration Schedule freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Drug Therapy, Combination freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Estramustine freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: administration & dosage Components - Type Classifier * is Major topic Yes content type: components (if present) include qualifier codings classifier: Flutamide freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: administration & dosage Components - Type Classifier * is Major topic Yes content type: components (if present) include qualifier codings classifier: Gonadotropin-Releasing Hormone freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: antagonists & inhibitors Components - Type Classifier * is Major topic No content type: components (if present) include qualifier codings classifier: Humans freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Male freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Middle Aged freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Neoplasm Invasiveness freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: pathology Components - Type Classifier * is Major topic Yes content type: components (if present) include qualifier codings classifier: Neoplasm Staging freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Probability freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Prognosis freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Prostatic Neoplasms freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: drug therapy Components - Type Classifier * is Major topic Yes component type: qualifier classifier: mortality Components - Type Classifier * is Major topic No component type: qualifier classifier: pathology Components - Type Classifier * is Major topic Yes content type: components (if present) include qualifier codings classifier: Survival Analysis freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Treatment Outcome freeToShare: true Components - Type Classifier * qualifier is not a major topic
components (if present) include qualifier codings
14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
Computable Publishing®: MEDLINE-to-FEvIR Converter
This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
National Library of Medicine, Index Section
Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
**BACKGROUND:** The present study was undertaken mainly to investigate whether chemohormonal therapy with estramustine phosphate plus luteinizing hormone-releasing hormone (LHRH) agonist has a more beneficial effect than the hormonal therapy with flutamide plus LHRH agonist for newly diagnosed patients with metastatic prostate cancer. **METHODS:** A total of 57 patients with metastatic prostate cancer aged 59-80 years (median 74 years) were entered in the study and were randomized to the treatment of estramustine phosphate (560 mg/day) plus LHRH agonist (estramustine group) or flutamide (375 mg/day) plus LHRH agonist (flutamide group) with stratification for the degree of performance status, histological differentiation and bone metastasis. **RESULTS:** Both of the treatment regimens were well tolerated with similar incidences of adverse drug reactions. The overall response rates (complete response plus partial response) at 12 weeks after treatment in the estramustine and flutamide groups were 76 and 55%, respectively. The median time to objective progression for the estramustine group (25.4 months) was longer than that of the flutamide group (14.6 months). The serum levels of follicle stimulating hormone and testosterone were significantly lower in the estramustine group. **CONCLUSIONS:** Chemohormonal therapy with estramustine phosphate plus LHRH agonist showed longer clinical progression-free survival than the hormonal therapy with flutamide plus LHRH agonist (P = 0.03), although there was no significant difference in the overall survival. A larger-scaled trial with more statistical power is required to clarify that the former regimen is more beneficial than the latter for newly diagnosed patients with advanced prostate cancer.
International journal of urology : official journal of the Japanese Urological Association
Classifier added by Computable Publishing LLC
Department of Urology, Kurume University School of Medicine, Kurume, Japan. noguchi@med.kurume-u.ac.jp